When solid food feels impossible, protein shakes designed for GLP-1 users can bridge the gap
ESSENCE Phase 3 semaglutide in MASH data supported FDA approval in March 2024 , creating a premium pricing tier in a disease category with USD 17.4 billion addressable market and no prior approved pharmacotherapy
During the median follow up of 15.9 months, 3.8% of the patients assigned to the study group experienced the primary outcome compared to 4.8% among those in the placebo
Facial Contouring with Kybella Even if youre doing everything right for your weight loss, sometimes the fat under your chin refuses to budge
This personalized insight allows your PlexusDx provider to optimize your semaglutide dose and consider alternative or complementary therapies if your genetic pattern suggests a less robust response to GLP-1 alone, ensuring you get maximum results from your treatment plan
Methyl--butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis
